Catheter Cardiovasc Interv 2021 Jun;97(7):1318-1319
Department of Cardiology, Long Beach Veteran's Administration Medical Center, Long Beach, California, USA.
Heart Lung Circ 2020 Feb 6;29(2):272-279. Epub 2019 Feb 6.
Monash Heart, Monash Medical Centre, Melbourne, Vic, Australia.
Background: Bifurcation percutaneous coronary intervention (PCI) remains a challenging frontier in interventional cardiology, especially in the setting of ST-elevation myocardial infarction (STEMI). We examined the procedural and clinical outcomes of this patient subset.Methods: We conducted a retrospective case-control study. Read More
Cardiol J 2018 18;25(4):443-458. Epub 2018 May 18.
Klinikum Frankfurt (Oder), Interventional Cardiology, Germany, Frankfurt/O, Germany; Institute of Cardiovascular Translation Research of the Atlantic (ICTRA), Berlin, Germany.
Background: Herein is hypothesised that a comprehensive optical coherence tomography (OCT)-guided implantation protocol for bioresorbable scaffolds (BRS) can improve expansion and apposition, thus resulting in better clinical outcomes, particularly in reducing thrombotic events.Methods: Patients considered suitable for BRS therapy in de novo coronary lesions underwent OCT. The predominant type of plaque was classified as lipidic, fibrous or calcific. Read More
JACC Cardiovasc Interv 2017 09;10(18):1867-1877
Department of Cardiology, Bern University Hospital, Bern, Switzerland.
Objectives: This study sought to investigate the effect of post-dilatation on angiographic and intracoronary imaging parameters in the setting of primary percutaneous coronary intervention comparing the everolimus-eluting bioresorbable scaffold (BRS) with the everolimus-eluting metallic stent (EES).Background: Routine post-dilatation of BRS has been suggested to improve post-procedural angiographic and subsequent device-related clinical outcomes.Methods: In the ABSORB STEMI TROFI II trial, 191 patients with ST-segment elevation myocardial infarction were randomly assigned to treatment with BRS (n = 95) or EES (n = 96). Read More
EuroIntervention 2017 Aug 4;13(5):e572-e577. Epub 2017 Aug 4.
Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Aims: The APPOSITION III registry evaluated the feasibility and performance of the STENTYS self-apposing stent in an ST-segment elevation myocardial infarction (STEMI) population. This novel self-apposing stent device lowers stent strut malapposition rates and therefore carries the potential to prevent stent undersizing during primary percutaneous coronary intervention (PCI) in STEMI patients. To date, no long-term data are available using this device in the setting of STEMI. Read More